NASDAQ: NEXINeximmune Inc Stock
$3.37-0.04 (-1.17%)
Updated Apr 26, 2024
NEXI Price
$3.37
Fair Value Price
$2.99
Market Cap
$4.62M
52 Week Low
$1.25
52 Week High
$28.70
P/E
-0.11x
P/B
1.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.45
Operating Cash Flow
-$31M
Beta
1.06
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NEXI Overview
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NEXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NEXI ($3.37) is overvalued by 12.86% relative to our estimate of its Fair Value price of $2.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NEXI ($3.37) is not significantly undervalued (12.86%) relative to our estimate of its Fair Value price of $2.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NEXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NEXI due diligence checks available for Premium users.
Be the first to know about important NEXI news, forecast changes, insider trades & much more!
NEXI News
Valuation
NEXI fair value
Fair Value of NEXI stock based on Discounted Cash Flow (DCF)
Price
$3.37
Fair Value
$2.99
Overvalued by
12.86%
NEXI ($3.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NEXI ($3.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NEXI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NEXI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
14.88x
Market
41.14x
NEXI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.32x
Industry
5.85x
NEXI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NEXI's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
NEXI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$8.6M
Liabilities
$5.1M
Debt to equity
1.45
NEXI's short-term assets ($5.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NEXI's short-term assets ($5.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NEXI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NEXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.8M
Investing
$0.0
Financing
$0.0
NEXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NEXI vs Biotech Stocks
Neximmune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.